Moreover, genetic alterations affecting bona fide cancer genes, such as TP53, RB1, and EGFR, appear to be restricted to borderline and malignant PTs (Piscuoglio et al., 2016b; Tan et al., 2015). The gene discussed is EGFR; the disease is cancer.